 Advertisement | ||||||||
 | ||||||||
|
||||||||
 |
 |
 |
 |
 |
 |
 |
||
|
From the Departments of Pharmacy and Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS (Wilson, Burton, Anderson); the Departments of Medicine and Pharmacy, University of Ottawa and Ottawa Hospital, Ottawa, Ont. (Wells, Lewis); and the Departments of Medicine and Pharmacy, University of Western Ontario and London Health Sciences Centre, London, Ont. (Kovacs, Martin).
Correspondence to: Dr. S. Jo-Anne Wilson, Assistant Professor of Pharmacy, Queen Elizabeth II Health Sciences Centre, Pharmacy Department — Victoria General, Rm. 2043, 1278 Tower Rd., Halifax NS B3H 2Y9; fax 902 473-6812; JoAnne.Wilson{at}cdha.nsheatlh.ca
Background: There is growing evidence that better outcomes are achieved when anticoagulation is managed by anticoagulation clinics rather than by family physicians. We carried out a randomized controlled trial to evaluate these 2 models of anticoagulant care.
Methods: We randomly allocated patients who were expected to require warfarin sodium for 3 months either to anticoagulation clinics located in 3 Canadian tertiary hospitals or to their family physician practices. We evaluated the quality of oral anticoagulant management by comparing the proportion of time that the international normalized ratio (INR) of patients receiving warfarin sodium was within the target therapeutic range ± 0.2 INR units (expanded therapeutic range) while they were managed in anticoagulation clinics as opposed to family physicians' care over 3 months. We measured the rates of thromboembolic and major hemorrhagic events and patient satisfaction in the 2 groups.
Results: Of the 221 patients enrolled, 112 were randomly assigned to anticoagulation clinics and 109 to family physicians. The INR values of patients who were managed by anticoagulation clinics were within the expanded therapeutic range 82% of the time versus 76% of the time for those managed by family physicians (p = 0.034). High-risk INR values (defined as being < 1.5 or > 5.0) were more commonly observed in patients managed by family physicians (40%) than in patients managed by anticoagulation clinics (30%, p = 0.005). More INR measurements were performed by family physicians than by anticoagulation clinics (13 v. 11, p = 0.001). Major bleeding events (2 [2%] v. 1 [1%]), thromboembolic events (1 [1%] v. 2 [2%]) and deaths (5 [4%] v. 6 [6%]) occurred at a similar frequency in the anticoagulation clinic and family physician groups respectively. Of the 170 (77%) patients who completed the patient satisfaction questionnaire, more were satisfied when their anticoagulant management was managed through anticoagulation clinics than by their family physicians (p = 0.001).
Interpretation: Anticoagulation clinics provided better oral anticoagulant management than family physicians, but the differences were relatively modest.
This article has been cited by other articles:
|
|
 |
|
  T. P. Moyer, D. J. O'Kane, L. M. Baudhuin, C. L. Wiley, A. Fortini, P. K. Fisher, D. M. Dupras, R. Chaudhry, P. Thapa, A. R. Zinsmeister, et al. Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience Mayo Clin. Proc., December 1, 2009; 84(12): 1079 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Cios, W. L. Baker, S. D. Sander, O. J. Phung, and C. I. Coleman Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis Am. J. Health Syst. Pharm., May 15, 2009; 66(10): 916 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Oake, C. van Walraven, M. A. Rodger, and A. J. Forster Effect of an interactive voice response system on oral anticoagulant management Can. Med. Assoc. J., April 28, 2009; 180(9): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gladstone, E. Bui, J. Fang, A. Laupacis, M. P. Lindsay, J. V. Tu, F. L. Silver, and M. K. Kapral Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated Stroke, January 1, 2009; 40(1): 235 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B Nichol, T. K Knight, T. Dow, G. Wygant, G. Borok, O. Hauch, and R. O'Connor Quality of Anticoagulation Monitoring in Nonvalvular Atrial Fibrillation Patients: Comparison of Anticoagulation Clinic versus Usual Care Ann. Pharmacother., January 1, 2008; 42(1): 62 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Franke, L. M. Dickerson, and P. J. Carek Improving Anticoagulation Therapy Using Point-of-Care Testing and a Standardized Protocol Ann. Fam. Med, January 1, 2008; 6(suppl_1): S28 - S32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, N. Oake, P. S. Wells, and A. J. Forster Burden of Potentially Avoidable Anticoagulant-Associated Hemorrhagic and Thromobembolic Events in the Elderly Chest, May 1, 2007; 131(5): 1508 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
|
|
C. van Walraven, A. Jennings, N. Oake, D. Fergusson, and A. J. Forster Effect of Study Setting on Anticoagulation Control: A Systematic Review and Metaregression Chest, May 1, 2006; 129(5): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, M. Man-Son-Hing, S. E. Straus, W. A. Ghali, D. Anderson, S. R. Majumdar, P. Gibson, J. L. Cox, M. Fradette, and for The Decision Aid in Atrial Fibrillation (DAAFI Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial Can. Med. Assoc. J., August 30, 2005; 173(5): 496 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Jones, P McEwan, C L. Morgan, J R Peters, J Goodfellow, and C J Currie Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart, April 1, 2005; 91(4): 472 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McGuire and P. P. Dobesh Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 289 - 307. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Smythe, W. E. Dager, and N. M. Patel Managing Complications of Anticoagulant Therapy Journal of Pharmacy Practice, October 1, 2004; 17(5): 327 - 346. [Abstract] [PDF]
|
|
|
|
 |
|
 C. van Walraven Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation Evid. Based Med., March 1, 2004; 9(2): 43 - 43. [Full Text] [PDF]
|
|
|
|
|
|
D. Massel Anticoagulation Can. Med. Assoc. J., February 17, 2004; 170(4): 447 - 447. [Full Text] [PDF]
|
|
|
|
|
|
G. Mazowita Anticoagulation Can. Med. Assoc. J., February 17, 2004; 170(4): 450 - 450. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Potter Anticoagulation Can. Med. Assoc. J., February 17, 2004; 170(4): 447 - 447. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Fitzmaurice Anticoagulation Can. Med. Assoc. J., February 17, 2004; 170(4): 447 - 450. [Full Text] [PDF]
|
|
|
|
|
|
D. R. Anderson, S. J.-A. Wilson, M. J. Kovacs, and P. S. Wells Anticoagulation Can. Med. Assoc. J., February 17, 2004; 170(4): 450 - 451. [Full Text] [PDF]
|
|
|
|
 |
|
 Other articles noted: 25 Jul 03 to 7 Nov 03 Evid. Based Nurs., January 1, 2004; 7(1): e1 - 1. [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, August 30, 2003; 327(7413): 510 - 510. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP | SEARCH |
|
|||||
|
Copyright 1995-2003, Canadian Medical Association. All rights reserved. ISSN 1488-2329
(e) 0820-3946 (p)
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. |
|||||
